Substitute 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation

US6534497B1 · kind B1 · utility

Assignees

• NuChem Pharmaceuticals Inc. · CA
• Children's Medical Center Corporation · US
• President and Fellows of Harvard College · US

Inventors

• Carlo Brugnara · Newton, US
• Jose Halperin · Brookline, US
• Rudolf Fluckiger · Brookline, US
• Emile Bellott · Beverly, US
• Richard John Lombardy · Littleton, US
• John J. Clifford · Arlington, US
• Ying-Duo Gao · Murfreesboro, US
• Reem M. Haidar · Woburn, US
• Eugene Kelleher · Somerville, US
• Adel Moussa · Burlington, US
• Yesh P. Sachdeva · Concord, US
• Minghua Sun · Libertyville, US
• Heather N. Taft · Littleton, US
• Michael Zeldin · Cambridge, US

Key dates

• Filing date: Sep 22, 2000
• Grant date: Mar 18, 2003
• Expiry date: Sep 22, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides substituted 11-phenyl-dibenzazepine compounds that are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.